Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Mallinckrodt
McKinsey
AstraZeneca
Baxter

Last Updated: January 21, 2020

DrugPatentWatch Database Preview

OMNIPAQUE 300 Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Omnipaque 300 patents expire, and what generic alternatives are available?

Omnipaque 300 is a drug marketed by Ge Healthcare and is included in two NDAs.

The generic ingredient in OMNIPAQUE 300 is iohexol. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the iohexol profile page.

Summary for OMNIPAQUE 300
Drug patent expirations by year for OMNIPAQUE 300
Recent Clinical Trials for OMNIPAQUE 300

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute (NCI)N/A
University of North Carolina, Chapel HillEarly Phase 1
Duke Clinical Research InstitutePhase 4

See all OMNIPAQUE 300 clinical trials

Pharmacology for OMNIPAQUE 300

US Patents and Regulatory Information for OMNIPAQUE 300

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare OMNIPAQUE 300 iohexol SOLUTION;INJECTION, ORAL, RECTAL 018956-003 Dec 26, 1985 RX Yes Yes   Start Trial   Start Trial   Start Trial
Ge Healthcare OMNIPAQUE 300 iohexol SOLUTION;INJECTION, ORAL, RECTAL 020608-002 Oct 24, 1995 RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for OMNIPAQUE 300

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge Healthcare OMNIPAQUE 300 iohexol SOLUTION;INJECTION, ORAL, RECTAL 018956-003 Dec 26, 1985   Start Trial   Start Trial
Ge Healthcare OMNIPAQUE 300 iohexol SOLUTION;INJECTION, ORAL, RECTAL 018956-003 Dec 26, 1985   Start Trial   Start Trial
Ge Healthcare OMNIPAQUE 300 iohexol SOLUTION;INJECTION, ORAL, RECTAL 018956-003 Dec 26, 1985   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Medtronic
Colorcon
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.